Brain metastases are an unfavourable manifestation of renal cell cancer. Currently, we have limited understanding of the tumour and immune biology of brain metastases and resistance factors to systemic therapy. The optimal approach to comprehensive treatment of brain metastases in renal cancer remains unclear. That is why it is important to search for additional prognostic factors in this category of patients. The aim of the study was to analyse prognostic predictors in patients with renal cancer metastases to the brain affecting survival rates. Materials and methods. We retrospectively analysed the data of 56 patients with brain metastases of RCC treated at the Moscow City Oncological Hospital No. 62 in Moscow and the City Clinical Oncological Dispensary (St. Petersburg) from 2006 to 2022, with a median follow-up of 45,6 months. 48 (85,7%) men prevailed in the study. Solitary brain metastases were detected in 19 (33,9%), and more than 2 metastases in 21 (37,5%). Intermediate and poor prognosis according to IMDC was established in 21 (37,5%) and 25 (44,6%), respectively, with low-differentiated tumours in the primary kidney tumour detected in 28 (50%) patients. Radiation therapy was given to 32 (57,1%) and metastasectomy to 33 (58,9%) patients. The study investigated clinical and morphological prognostic factors influencing survival rates in patients with brain metastases of RCC. Statistical analysis was performed using Statistica 10.0 software packages (StatSoft, USA) by constructing Kaplan-Meier curves and survival tables, building a mathematical model of survival. Results. The 3- and 5-year OS in patients with brain metastases of RCC (n=56) was 43% and 22%, respectively, with a median OS of 22,3 months. In single factor analysis in patients with renal cancer brain metastases, ECOG status (p=0,0047), number of brain metastases (p